When Multiple Antidepressants Fail: A Possible New Option for Major Depression

Are you scrambling for options because patients can’t find relief from major depression, even after trying multiple antidepressants? A new clinical trial could add a potent weapon to your arsenal. Researchers are looking at the role of cariprazine, an antipsychotic drug that acts as a partial agonist on D₂ and D₃ receptors, in patients who suffer from partial response, treatment-resistant or refractory depression. Here are the details.

Research Gender Gap: Legislation Pushes for More Females Participants

Women may make up slightly more than half of the population of the United States, but that is far from true in the clinical research population, where only about a third of cardiovascular  trial participants are female. In fact, many clinical studies don’t even report gender breakdowns. Find out about new bipartisan legislation introduced to remedy that.

Could Non-Stimulant in Development Help Your Adult ADHD Patients?

When adults have ADHD, the whole family can be affected: Work deadlines might be missed, bills don’t get paid, spouses and children complain of inattention. Current drugs often are only somewhat effective in treating the disorder, and side effects can make them intolerable. Now, a new drug is showing promise in treating adult ADHD. Here are the details.

Investment in Medical Research Declines in U.S., Rises Elsewhere

The increase in funding for medical research may be leveling off in the United States, but the need for medical innovation is as critical as ever. That’s according to a recent report and commentary in JAMA, showing that the annual growth rate for medical research investment fell to 0.08% from 2004 to 2012, compared to 6% in the previous decade. What does that really mean for early discovery efforts?